New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 5, 2014
09:00 EDTABT, MRK, SNYAbbott joins peers in considering sale of mature drugs, Reuters says
Abbott (ABT) is working with Morgan Stanley (MS) to find a potential buyer for a portfolio of its off-patent drugs, Reuters said late Friday, citing people familiar with the matter. Abbott's portfolio of assets being considered for sale could fetch more than $5B, the report quoted the sources as having said. Prior reports have indicated that Merck (MRK) and Sanofi (SNY) are also exploring potential sales of their portfolios of mature drugs. Reference Link
News For ABT;MRK;SNY From The Last 14 Days
Check below for free stories on ABT;MRK;SNY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 28, 2014
15:47 EDTMRKNotable companies reporting before tomorrow's open
Subscribe for More Information
14:03 EDTMRKEarnings Preview: Merck's pharmaceutical sales dependent on newer drugs
Subscribe for More Information
11:07 EDTABTLeerink medical devices analyst holds an analyst/industry conference call
Medical Devices Analyst Antalffy, along with MEDACorp Specialist Arie Pieter Kappetein, MD, PhD and Bernhard Meier, MD, assess EU cardiology trends on an Analyst/Industry conference call to be held on July 31 at 3 pm.
10:36 EDTMRKMerck August weekly volatility elevated into Q2 and outlook
Merck August weekly call option implied volatility is at 26, August is at 16, September is at 15, January is at 16; compared to its 26-week average of 18 according to Track Data, suggesting large near term price movement into the expected release of Q2 result on July 29.
09:02 EDTSNYSanofi, InnerWorkings sign global marketing partnership
Subscribe for More Information
07:30 EDTABTQ1 Productions to hold a conference
Subscribe for More Information
07:26 EDTABTAmerican Association for Clinical Chemistry to hold annual meeting
Subscribe for More Information
06:52 EDTABTFormer official says Obama could limit inversion deals, NY Times reports
President Obama could limit tax inversion deals on his own authority, said Stephen Shay, former deputy assistant Treasury secretary for international tax affairs in the Obama administration, according to The New York Times. A 1969 law gives the president the ability to restrict inversion deals, said Shay, who also worked in the Reagan administration, the newspaper stated. Among the deals or possible transactions that involve inversion are Mylan's (MYL) acquisition of Abbott (ABT), Medtronic's (MDT) acquisition of Covidien (COV) and Valeant's (VRX) proposed takeover of Alletgan (AGN). Reference Link
July 25, 2014
07:32 EDTABTAmerican Veterinary Medical Association to hold a conference
Subscribe for More Information
06:30 EDTABTObama calls on Congress to end inversion deals, NY Times reports
Subscribe for More Information
July 24, 2014
14:35 EDTABTObama to call for elimination of tax inversion deals, NY Times says
President Obama will call on Congress today to eliminate the tax inversion loophole, according to The New York Times. Among the deals or possible transactions that involve inversion are Mylan's (MYL) acquisition of Abbott’s (ABT), Medtronic's acquisition of Covidien (COV)and Valeant's (VRX) proposed takeover of Alletgan (AGN)Reference Link
08:32 EDTMRKMerck initiates Phase 3 study of Letermovir
Subscribe for More Information
July 23, 2014
10:27 EDTABTHouse Energy & Commerce Committee to hold a hearing
Subscribe for More Information
06:45 EDTABTLawmakers divided on inversion deals, NY Times says
Subscribe for More Information
July 21, 2014
07:21 EDTMRKGilead could be hurt by new HCV drugs, says Wells Fargo
Noting that data on a new Merck (MRK) HCV treatment is expected in November, Wells Fargo thinks Merck's HCV drug could be combined with Gilead's (GILD) Sovaldi to shorten the duration of treatment to four weeks. Other companies could take similar actions, and Gilead's per patient revenues would be significantly reduced if this occurs, the firm warned. However, it continues to have an upbeat outlook on Gilead heading into what it sees as a strong quarter and is still upbeat on the company's long-term HCV opportunity. It keeps an Outperform rating on Gilead.
07:11 EDTSNYInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information
06:43 EDTMRKGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information
July 18, 2014
16:47 EDTABTMarket ends week higher as earnings, M&A offset geopolitical tensions
Subscribe for More Information
12:51 EDTABTKey GOP senator signals readiness for inversion deal, The Hill says
Subscribe for More Information
July 17, 2014
07:06 EDTABTAbbott price target raised to $47 from $42 at Stifel
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use